Article Text
Abstract
Intravenous Ferric Derisomaltose (IV FDM) is increasingly used for the treatment of iron deficiency anaemia in paediatric gastroenterology patients. Our aim was to review the safety and effectiveness data of IV FDM in two paediatric tertiary gastroenterology centres (Hospitals A & B).
A retrospective case notes review of all paediatric gastroenterology patients receiving IV FDM between 2018 and 2023 was undertaken, following approval by the Clinical Audit and Effectiveness team. Baseline demographics, indication for IV iron, previous oral iron treatment, monitoring pre and post infusion including haematological and biochemical parameters, adverse events and need for further IV iron infusions were recorded. All patients were administered a dose of 20mg/kg IV FDM with a maximum dose of 1 gram in Hospital A and 1.5 grams in Hospital B.
A total of 65 patients who received 78 IV FDM infusions, were identified from Hospitals A and B, during this period. A majority, 49/65 (75.4%), had Inflammatory bowel disease, with a median age at iron infusion of 12.8 years (IQR: 9.6–15.2) and a median weight of 36.5 Kg (IQR: 24.1–58.5). A significant, rapid and well-maintained increase in median Haemoglobin (HB) levels was observed after IV FDM, paralleled by MCV trends (table 1). No alterations in phosphate levels were reported after the IV FDM infusion, with data available for 80% of the entire cohort. There were no alterations noted in liver and renal function tests. Overall, 53/65 (81%) patients recovered their anaemia after IV FDM with 9/53 (17%) re-dropping HB and requiring further iron supplementation. Regarding IV FDM safety, 3/65 (4.5%) patients had to discontinue the infusion, only one due to an allergic reaction with chest pain, decreased O2 saturations and cutaneous rash.
Overall, our multicentre real-world data showed that IV FDM was safe, well tolerated and demonstrated good clinical effectiveness in paediatric gastroenterology with no significant biochemical changes induced post infusion.